Comparative Pharmacology
Head-to-head clinical analysis: KELNOR versus MIBELAS 24 FE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KELNOR versus MIBELAS 24 FE.
KELNOR vs MIBELAS 24 FE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combined oral contraceptive; inhibits ovulation by suppressing gonadotropin release (FSH and LH) primarily via progestational activity; increases viscosity of cervical mucus to inhibit sperm penetration; alters endometrium.
Combination hormonal contraceptive: ethinyl estradiol suppresses LH and FSH, primarily inhibiting ovulation; drospirenone is a progestin with anti-mineralocorticoid and anti-androgenic activity, increasing cervical mucus viscosity and altering endometrial morphology.
KELNOR (norethindrone acetate and ethinyl estradiol) is a combined oral contraceptive. Typical adult dose: 1 tablet (norethindrone acetate 1 mg/ethinyl estradiol 20 mcg) orally once daily for 21 days, followed by 7 placebo tablets, starting on day 1 of menstrual cycle.
One tablet orally once daily for 24 days followed by 4 placebo tablets. Each tablet contains 75 mcg desogestrel and 0.02 mg ethinyl estradiol.
None Documented
None Documented
Terminal elimination half-life 12-15 hours; clinically relevant for once-daily dosing.
Drospirenone: ~30 hours; Ethinyl estradiol: ~17 hours. Steady-state reached after ~10 days for drospirenone.
Primarily renal excretion of unchanged drug (70-80%) and glucuronide conjugate (10-15%); biliary/fecal elimination accounts for <5%.
Drospirenone: 40-50% renal as metabolites, <10% unchanged; ~50% fecal. Ethinyl estradiol: ~40% renal, 60% fecal.
Category C
Category C
Oral Contraceptive
Oral Contraceptive